TUCSON, Ariz., Aug. 09, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments and reagents for molecular profiling applications, today reported financial results for the three and six month periods ended June 30, 2016.
TUCSON, Ariz., July 28, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that the Company will release 2016 second quarter financial results after market close on Tuesday, August 9, 2016. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Tuesday, August 9 to discuss these results and answer questions.
TUCSON, Ariz., July 28, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that its management will be presenting at the Canaccord Genuity Growth Conference on Thursday, August 11, 2016 in Boston.
Join us Tuesday, July 26, 2016 for a GenomeWeb webinar.
HTG will host a GenomeWeb webinar with Eric Schordan, Head of Molecular Diagnostic Department, Firalis and TcLand Expression: New Tools for Biomarker Discovery Promise Personalized Treatment for Rheumatoid Arthritis
TUCSON, Ariz., July 20, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that it has obtained CE-IVD marking for its HTG EdgeSeq DLBCL Cell of Origin Assay and next-generation sequencing (NGS) based HTG EdgeSeq system. There are approximately 79,000 non-Hodgkin lymphomas per year in the European Union, and as many as 40% of those are diagnosed as diffuse large B-cell lymphoma (DLBCL). The 2016 updates to the World Health Organization (WHO) guidelines for the classification of lymphoid neoplasms have been reported to require subtyping of DLBCL tumors as activated B‑cell (ABC) or germinal center B-cell (GCB).
TUCSON, Ariz. and HUNINGUE, France, July 06, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, and Firalis S.A. (“Firalis”), a provider of bioanalytical services and biomarker-based products to biopharma, to biotechnology companies, and to academia, today announced an agreement to develop a next‑generation sequencing (NGS)-based theranostic tool to identify likely non-responders from responders to anti‑TNFα therapy for rheumatoid arthritis (RA).
TUCSON, Ariz., June 23, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced the introduction of its Tucson‑based VERI/O laboratory service, offering laboratory support for its biopharma clients in biomarker research and companion diagnostic development. The VERI/O laboratory service formalizes and expands HTG’s traditional service offerings, including molecular profiling of retrospective cohorts to support development of targeted and immuno-oncology therapies, building custom research-use-only (RUO) assays to support early stage clinical programs, and developing companion diagnostic assays for use in Phase III registration trials.
TUCSON, Ariz., June 20, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for NGS-based molecular profiling applications, today announced the appointment of Suzanne Hill as Vice President of North American Capital Sales.
TUCSON, Ariz. and LOS ANGELES, June 06, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, and Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the acceptance of a study by the American Society of Clinical Oncology (ASCO) for presentation at their 2016 Annual Meeting, June 3–7, 2016 in Chicago, IL.
Join HTG Molecular Diagnostics at the 2016 Annual ESHG meeting to learn more about HTG’s NGS-based sequencing assays that are automated on the HTG EdgeSeq system.
TUCSON, Ariz., May 12, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced a research collaboration agreement with Bristol-Myers Squibb (NYSE:BMY) to evaluate the potential for immuno-oncology molecular profiling in multiple tumor types. The collaboration between HTG and Bristol-Myers Squibb will utilize the next generation sequencing (NGS)-based HTG EdgeSeq system as a tool for use in support of Bristol-Myers Squibb’s translational research activities.
TUCSON, Ariz., May 12, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments and reagents for molecular profiling applications, today reported financial results for the three months ended March 31, 2016.
Page last updated March 20, 2023